Kajeno Abbott e phatlalalitse hore US Food and Drug Administration (FDA) e amohetse pontšo e atolositsoeng bakeng sa k'hamphani ea CardioMEMS™ HF System ho ts'ehetsa tlhokomelo ea batho ba bangata ba phelang le lefu la pelo. Ka pontšo e atolositsoeng, bakuli ba eketsehileng ba limilione tse 1.2 ba US1 joale ba lokeloa ho rua molemo ka ho beha leihlo le tsoetseng pele ka sensor ea CardioMEMS, e bontšang keketseho e kholo ho feta palo ea batho ba teng hona joale. Sensor e fana ka sistimi ea temoso ea pele e nolofalletsang lingaka ho itšireletsa khahlanong le ho hloleha ha pelo ho mpefalang.
Batho ba Amerika ba fetang limilione tse 6.2 ba na le lefu la pelo2, 'me ho na le liphuputso tse reretsoeng ho habeli3 ka 2030. Le hoja ho hloleha ha pelo e le lefu le sa foleng, mekhoa ea bongaka e kang CardioMEMS e ka fa bakuli le lingaka tsa bona temohisiso e sebetsang ho thusa ho laola ho hloleha ha pelo pele e tsoela pele ho fihlela qetellong. . Sensor ea CardioMEMS ke sesebelisoa sa boholo ba paperclip seo, hang ha se behiloe ka har'a mothapo oa pulmonary nakong ea ts'ebetso e fokolang, e lekola liphetoho tsa khatello tse bontšang ho senyeha ha pelo ho mpefalang. Sensor e fetisetsa likhatello tsa letsatsi le letsatsi ho sehlopha sa kliniki sa mokuli ka mohala - e lumella lingaka ho etsa liphetoho tsa kalafo ho loants'a tsoelo-pele ea ho hloleha ha pelo ea morao-rao ha li ntse li matlafatsa mokuli ho laola boemo ba bona ho tloha kae kapa kae.
The CardioMEMS HF System e qalile ho amoheloa ka 2014 bakeng sa ho sebelisoa ho New York Heart Association (NYHA) Bakuli ba ho hloleha ha pelo ba Sehlopha sa III ba nang le lefu la pelo pele ho sepetlele nakong ea selemo se fetileng. Pontšo e ncha e lumella sensor ea CardioMEMS hore e sebelisoe ke batho ba phelang le lefu la pelo la Sehlopha sa II le ho bakuli ba kenang tlhahlobo ea mali e bontšang litekanyetso tse phahameng tsa biomarkers tse tsejoang e le li-peptide tsa natriuretic, tse bontšang ho senyeha ha pelo ho mpefala.
Philip B. Adamson, MD, ofisiri e ka sehloohong ea bongaka khoebong ea Abbott ea lefu la pelo, ho boletse Philip B. Adamson, MD. “Pontšo ena e atolositsoeng e bolela hore lingaka li ka phekola batho ba bangata ba tšoeroeng ke lefu la pelo pele ho nako, li fana ka monyetla oa ho thibela ho utloa bohloko ho eketsehileng ’me mohlomong ho qoba tsoelo-pele ea morao-rao e ka bang le phello e tebileng boleng ba bophelo ba motho.”
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- The new indication allows the CardioMEMS sensor to be used by people living with Class II heart failure and for patients who undergo a blood test showing elevated levels of biomarkers known as natriuretic peptides, which indicate worsening heart failure.
- While heart failure is a chronic disease, medical options like CardioMEMS can provide patients and their doctors with actionable insights to help manage heart failure before it progresses to a later stage.
- The CardioMEMS HF System was initially approved in 2014 for use in New York Heart Association (NYHA) Class III heart failure patients with a prior heart failure hospitalization within the last year.
